CUV
Clinuvel Pharmaceuticals
Pharmaceuticals, Biotechnology & Life Sciences
Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin pep...
Pharmaceuticals
Biotechnology
SCENESSE
Photoprotection
Shorted
short percentage
reported short positions
total shares on issue
About
website
industry
address
Key Metrics
market cap
$575.30Mp/e ratio15.92
eps$0.72
dividend yield45.00%
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Short Position Trends
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns